This live session took place on Wednesday, June 21st, 2017.
The webinar will provide a detailed picture of key stakeholders in the road to market access in the EU5. For each country, the webinar will provide an overview of how the health technology assessment (HTA) process and payer policy will impact prescription of atopic dermatitis therapies.
During this presentation you'll learn:
- What is the market access landscape in the EU5?
- What are payer and physician perspectives on promising but costly emerging agents such as dupilumab?
- What key market access challenges will manufacturers of novel atopic dermatitis therapies face?
- What can drug manufacturers do to encourage optimal pricing and reimbursement terms and to drive uptake?
Presented by Yulia Privolnev, Principal Analyst, Market Access Insights